ArticleJournal of nephrology2025
Sustained renal response with belimumab in children with new-onset lupus nephritis.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBelimumab is approved for treating systemic lupus erythematosus (SLE) in children over 5 years old; however, its efficacy and safety in pediatric SLE patients require further validation. This study aimed to evaluate the impact of belimumab on the long-term cumulative probability of sustained renal response and disease flare in children with lupus nephritis (LN), to inform clinical decision-making.
methodsWe included a total of 96 children with LN in our study. The patients were part of a prospective cohort study and were divided into two groups: belimumab group (68 cases) and standard treatment (group (28 cases). We compared remission rates, flare rates, and adverse event incidence between these two groups.
resultsAfter 152 weeks of follow-up, belimumab increased the renal response and complete renal response rates by 16.7% [odds ratios (OR) = 5.38 (1.33, 15.12)] and 24.7% [OR = 2.74 (1.04, 7.19)]. Belimumab significantly reduced the risk of LN flare, with a 46.2% lower flare rate in the belimumab group compared to the standard treatment group. There was no significant difference in long-term cumulative probability of complete remission between the belimumab and standard treatment groups (P = 0.081), and the standard treatment group had a higher flare rate (P = 0.004).
conclusionsAdding belimumab to standard treatment may effectively maintain long-term kidney function and reduce LN flares, making it an effective and safe biologic agent.
Indexed as
Identifiers
41233651What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.